5 MINUTES WITH: Jim Miller, DCAT Research and Benchmarking Committee
By

By
DCAT Value Chain Insights’ “5 Minutes With,” part of the new DCAT Member Community section, features interviews with industry leaders on issues impacting the bio/pharmaceutical manufacturing value chain and other business…

Women Leaders in Pharma Interview: Fran Zipp, Lachman Consultant Services
By

By
The latest interview in the DCAT Alliance for Industry Women Committee’s Women Leaders in Pharma: An Interview Series features Frances (Fran) Zipp, President & CEO of Lachman Consultant Services, Inc.…

Women Leaders in Pharma Share Insights in Latest DCAT Webinar
By

By
On October 28, the DCAT Alliance for Industry Women Committee held a complimentary webinar titled “Lessons in Leadership: An Exclusive Live Chat with Women Leaders in Pharma.” During the hourlong…

DCAT Announces Plans for In-Person DCAT Week 2022
By

By
On November 3, 2021, the Drug, Chemical & Associated Technologies Association (DCAT) announced preliminary plans for its flagship event, DCAT Week, including confirmation that the event will take place in…

Listen to DCAT Value Chain Insights on the Go
By

By
Stay up-to-date on the latest in-depth analysis on issues impacting the business of pharmaceutical development and manufacturing—on the go! We are pleased to offer the DCAT Value Chain Insights podcast,…

Focus of 2022 DCAT Research & Benchmarking Report is Announced 
By

By
Evaluate your company’s best practices and learn from industry peers with DCAT Research & Benchmarking reports. Beginning this month, DCAT’s Research and Benchmarking Committee will begin distributing its 2022 survey…

FDA OKs Boosters for COVID-19 Vaccines
By

By
The US Food and Drug Administration is amending emergency use authorizations for COVID-19 vaccines by Moderna and Johnson & Johnson to allow for booster doses in certain eligible populations. The…

Novartis in Mfg Pact for Pfizer’s COVID-19 Vaccine
By

By
Novartis has signed a new agreement to fill–finish Pfizer’s/BioNTech’s COVID-19 vaccine. Novartis will use its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.…

Takeda in $4-Bn-Plus Cell- and Gene-Therapy Pacts
By

By
Takeda has entered into two separate pacts, worth up to more than $4 billion, for developing cell and gene therapies. Under the first pact, Takeda has formed a research and…

FDA OKs BI’s Interchangeable Biosimilar of Humira
By

By
The US Food and Drug Administration has approved the first interchangeable biosimilar product to AbbVie’s blockbuster drug, Humira (adalimumab). Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), originally approved in August 2017, is both…